Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum DRI Healthcare Trust T.DHT.UN

Alternate Symbol(s):  DHTRF

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term. Geographically, it has a presence... see more

TSX:DHT.UN - Post Discussion

DRI Healthcare Trust > Updated Assessment
View:
Post by retiredcf on Apr 10, 2022 10:53am

Updated Assessment

They were questioned following the comments from IA Capital. Naturally I disagree with their final statement because I like to jump on board before the majority of investors become aware. GLTA

Revenues have mostly remained flat quarter-over-quarter for the past year, and its profit margins have remained fairly elevated. Debt levels are low, it generates positive free cash flows, and it has strong cash and equity positions. It pays a decent dividend of 3.6% and forward sales growth is good. It is a smaller cap company with limited history, but most financials look good here. We do not see the company undergoing explosive growth, but it may see modest growth in the low double-digits. Management looks pretty good here, with the Chairman having a long background in senior government roles, president of Coastal Contacts and serves on the board of other public companies. The CEO, Behzad Khosrowshahi, has been transforming the company since the private acquisition of Drug Royalty Corp in 2002, and has previously held senior roles at Future Shop and began his career at Deloitte. We think it looks interesting but would like to give it more time before stepping in here.  (5iResearch)

 
Comment by mjh9413 on Apr 12, 2022 1:29am
Thanks for that retiredcf but I don't get their comments. Hey maybe I'm wrong but FTM qtly divs based on last two wud result in 4.5% yield (USD7.5cents on $8.35sp) and that does not take account of special div that is likely to occur in last qtr. And the comment on sequential or any comparative trends in revs ignores the fundamental streaming pattern  that one can expect from such ...more